In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Institutionalizing Externalization At Big Pharma – The Third Leg

Executive Summary

The pharmaceutical industry has a hard time saying goodbye to strategic assets. In fact, it’s much more adept at welcoming new ones: diversification – either geographic or into areas beyond pure-play pharmaceuticals – has become commonplace. But pharma needs to overcome its entrenched resistance to asset externalization, which should become a critical third leg in its attempts to build long-term shareholder value. Strategic, almost biotech-like externalization strategies should move from a peripheral to a core part of pharma’s activities. Why haven’t they already been embraced?

You may also be interested in...



Too Big To Succeed: Where Are Large Pharmas Heading?

Company scale is a negative predictor of value creation among biopharmaceutical companies, says a new analysis by L.E.K. Consulting, and industry’s largest companies have simply become too large to generate significant shareholder return going forward. How can the largest pharmaceutical companies adapt to an environment where they’ve become too big to succeed?

Deals Of The Week: United Therapeutics/Ascendis, Baxter/Onconova, Bionomics/Eclipse

The growing importance of emerging markets was a primary discussion point Sept. 17-19 at Elsevier’s Pharmaceutical Strategic Alliances conference in New York

Biogen Idec Buys Stromedix, Bringing IPF Candidate Full Circle

Started by a former Biogen executive, Stromedix licensed STX-100 from Biogen and developed it into an attractive candidate in an area the reshaped big biotech wants to pursue.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC142523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel